is one of the foremost world authorities on potent compound containment
and aseptic process isolators. Over thirty years experience in the
specialized field of Pharmaceutical Cleanrooms and associated processes
and equipment, he has been involved with building redevelopment
for cleanroom and advanced technology use. Mr. Wilkins has a track
record of successful projects for pharmaceutical companies involving
drug metabolism, animal facilities, large quantity fume hood development,
and high containment pilot plant and site master plan development.
In 1991 Mr.
Wilkins founded a company in the United Kingdom specializing in
isolators for potent and aseptic pharmaceutical processing. It was
later acquired by Tanshire Holdings and now Kynoch PLC. Responsible
positions held were Managing Director and Business Development.
He also guided new technologies development and managed new concepts.
In this position, Julian is responsible for several developments
and inventions such as:
Chamber Offload requiring a 200 nannograms OEL limit
Potent Formulation type tested and manufactured for stability
liquid transfer system co-patented by Mr. Wilkins
first contained aseptic syringe filling in an unclassified room
with FDA and EEC product approval for non-terminally sterilizable
Nitrogen environment Offload of Cephalosporins with six units
and many other developments.
is a qualified Architect in the United Kingdom, educated at Oxford
School of Architecture 1966-72.
He is a member
of the International Society for Pharmaceutical Engineering (ISPE),
founding member of the UK affiliation, Committee Person of the year
in 1991, and member of the, Education, Membership and currently
the Marketing Advisory Council committees.
has lectured and authored many papers on potent compound containment
and isolators for aseptic processes.